Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Complement C3a receptor–mediated vascular dysfunction: a complex interplay between aging and neurodegeneration
Kanchan Bhatia, … , Adam Kindelin, Andrew F. Ducruet
Kanchan Bhatia, … , Adam Kindelin, Andrew F. Ducruet
Published January 4, 2021
Citation Information: J Clin Invest. 2021;131(1):e144348. https://doi.org/10.1172/JCI144348.
View: Text | PDF
Commentary

Complement C3a receptor–mediated vascular dysfunction: a complex interplay between aging and neurodegeneration

  • Text
  • PDF
Abstract

Vascular dysfunction resulting in compromised blood-brain barrier (BBB) integrity is evident in aging and disease. Although the complement C3a/C3a receptor (C3a/C3aR) axis influences normal brain aging and disease progression, the mechanisms governing endothelial C3aR–mediated neurovascular inflammation and BBB permeability remain unexplored. In this issue of the JCI, Propson et al. investigated endothelial C3a/C3aR signaling in normal, aged, and neurodegenerative mouse models. Endothelial C3aR signaling modulated age-dependent increases in VCAM1, initiated peripheral lymphocyte infiltration, and enhanced microglial activity. Increased calcium release downstream of C3aR signaling disrupted the vascular endothelial cadherin (VE-cadherin) junctions, increased BBB permeability, and degraded vascular structure and function. Mice lacking C3aR (C3ar1–/–) and mice treated with a C3aR antagonist showed attenuated age-related microglial reactivity and neurodegeneration. These results confirm that complement-mediated signaling impacts vascular health and BBB function in normal aging and neurodegenerative disease, suggesting that complement inhibitors represent a therapeutic option for cerebral microvascular dysfunction.

Authors

Kanchan Bhatia, Saif Ahmad, Adam Kindelin, Andrew F. Ducruet

×

Figure 1

Model for C3a-mediated neurovascular inflammation and BBB permeability.

Options: View larger image (or click on image) Download as PowerPoint
Model for C3a-mediated neurovascular inflammation and BBB permeability.
...
Top: With age, C3aR-mediated endothelial cell VCAM1 expression increases in the cortex and hippocampus and VE-cadherin is downregulated. Subsequent endothelial cell calcium (Ca2+) release disrupts tight junctions, which increases BBB permeability. RBCs, plasma proteins, and leukocytes can infiltrate the vasculature where they can adhere, roll, and then leak into extravascular tissue. Bottom: Propson et al. (6) showed that treatment with a C3aR antagonist blocked C3a from binding to C3aRs, preventing pathological changes in tight junctions and subsequent leukocyte extravasation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts